IMEX   05356
INSTITUTO DE MEDICINA EXPERIMENTAL
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Expression Dynamics Of Arginase-1 Accompanies The Achieved Molecular Response To Imatinib In Chronic Myeloid Leukemia Patients
Autor/es:
LINCANGO M; TARQUI M; LARRIPA I; BORDONE J; NEGRI ARANGUREN P; BELLI C; TOLOZA, MARÍA JAZMÍN; MARIANO R; ENRICO A
Reunión:
Congreso; ESH 2nd How to Diagnose and Treat CML/MPN; 2021
Institución organizadora:
European School of Haematology (ESH)
Resumen:
Purpose Imatinib remains as the preferred tyrosine kinase inhibitor (TKI) to treat chronic myeloid leukaemia (CML) patients. Besides its direct action targeting BCR-ABL1, TKI therapy may also influence the anti-tumour response. A broadly compromised immune system has been described at time of diagnosis supporting for a suppression of anti-CML immune responses. These abnormalities include an expansion of the suppressive immune cell populations, myeloid derived suppressor cells (MDSCs) and regulatory T cells (Treg), and dysfunctional effector NK- and T-immune responses. The use of tyrosine kinase inhibitors seems to restore this compromised immune system leading to a re-activation of the effector-mediated immune surveillance. Here, we describe the expression dynamics of TNF, IFNG, IL6, IL10, TGBF1, CIITA, TBET and ARG1 during the first year on imatinib therapy.Methods Gene expression was evaluated in 132 peripheral blood samples from 79 CML patients, including 34 who were serially followed and 26 healthy controls. Materials were collected at the time of diagnosis (n=23) or under imatinib treatment (400 mg) at 3 (n=41), 6 (n=42) or 12 (n=26) months and were classified according to the ELN criterion for optimal molecular response at each time of treatment. An aliquot of the stored sample used to monitor BCR-ABL1 levels was retro-transcribed to cDNA and gene expression was quantified by real-time PCR.Results An elevated expression of ARG1 (Mann-Whitney test p